Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points

Objectives: A phase III, 24-weeks Chinese clinical trial demonstrated that efficacy and safety outcomes of treatments with 40 mg/0.8 ml HS016 (n = 416) or adalimumab (n = 232) for active ankylosing spondylitis (AS) patients was comparable. In the present study, a subanalysis of the clinical trial wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750525/
https://www.ncbi.nlm.nih.gov/pubmed/33364967
http://dx.doi.org/10.3389/fphar.2020.606497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750525/
https://www.ncbi.nlm.nih.gov/pubmed/33364967
http://dx.doi.org/10.3389/fphar.2020.606497

Ejemplares similares